Dipal Doshi - 01 Jul 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
President and CEO, Director
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Issuer symbol
TRDA
Transactions as of
01 Jul 2022
Net transactions value
$0
Form type
4
Filing time
06 Jul 2022, 16:15:35 UTC
Previous filing
29 Jun 2022
Next filing
29 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Stock Option (Right to Buy) Award $0 +90,750 $0.000000 90,750 01 Jul 2022 Common Stock 90,750 $12.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the option shares shall vest and become exercisable on July 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on July 1, 2026.